Evidence map›Paper›PMID 41787033›Full record

ArticleDiscover oncology2026

IGF2BP3 promotes the muscle invasion of bladder cancer via PPARγ dysregulation.

Jing-Yi Cao, Hua Peng, Guang-Yue Wang, Ping-An Chang, Wen-Tao Yao, Qian Wang, Jie-Zhou, Gui-Hua Zhang, Heng Wang, Jia-Cheng Wu and 4 more

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jing-Yi CaoDepartment of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Huan Cheng Road, No. 131, Xuzhou, 221000, Jiangsu, China.
Hua Peng *Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Huan Cheng Road, No. 131, Xuzhou, 221000, Jiangsu, China.
Guang-Yue Wang *Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Huan Cheng Road, No. 131, Xuzhou, 221000, Jiangsu, China.
Ping-An ChangDepartment of Urology, Dongtai People Hospital, Yancheng, China.
Wen-Tao YaoDepartment of Urology, Suzhou TCM Hospital, Nanjing University of Chinese Medicine, Suzhou, China.
Qian WangDepartment of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Huan Cheng Road, No. 131, Xuzhou, 221000, Jiangsu, China.
Jie-ZhouDepartment of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Huan Cheng Road, No. 131, Xuzhou, 221000, Jiangsu, China.
Gui-Hua ZhangDepartment of Hematology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.
Heng WangDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jia-Cheng WuDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Sha-Sha LiDepartment of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Huan Cheng Road, No. 131, Xuzhou, 221000, Jiangsu, China.
Quan-Lan GaoDepartment of Urology, Xuzhou New Health Hospital, Xuzhou, China.
Chang-Song PeiDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Qi-Chao WangDepartment of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Huan Cheng Road, No. 131, Xuzhou, 221000, Jiangsu, China. wangqc1986@126.com.

Funding

2023 Xuzhou City to promote science and technology innovation special fund key projects KC232312023 Xuzhou City to promote science and technology innovation special fund key projects KC232332023 Xuzhou Municipal Health Commission science and Technology project youth projects XWKYHT202300012024 Xuzhou Municipal Health Commission science and Technology project youth projects XWKYHT2024001Jiangsu Provincial Administration of Traditional Chinese Medicine Project MS2021075Science and Technology Project of Suzhou City of China SYW2024133
6 · The paper itself

Abstract

Bladder cancer (BC) is a common urinary-tract malignancy that, once it progresses to the muscle‐invasive form (MIBC), adopts a markedly more aggressive behavior and is linked to significantly poorer patient outcomes. Despite extensive investigation, the molecular drivers of MIBC progression have yet to be fully elucidated. In this study, we demonstrate that IGF2BP3 is markedly upregulated, whereas PPARγ is significantly downregulated, in MIBC tissues compared with non–muscle–invasive disease, and that these reciprocal expression changes correlate with enhanced muscle invasion and adverse clinical outcomes. Comprehensive in vitro analyses reveal that elevated IGF2BP3 modulates BC cell motility, with overexpression enhancing migration and invasion and knockdown reducing these processes, while effects on proliferation and apoptosis were minimal. Mechanistic investigations further indicate that IGF2BP3 manipulation in vitro modulates PPARγ mRNA levels and PPARγ knockdown or overexpression respectively augments or abrogates IGF2BP3‐driven cell motility. Collectively, our findings define a novel IGF2BP3/PPARγ signaling axis that contributes to the aggressive behavior of MIBC and suggest that targeting this pathway may offer new avenues for therapeutic intervention.

Indexed as

Bladder cancerIGF2BP3Muscle-invasivePPARgamma

Identifiers

PMID41787033
PMCPMC13076712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.